

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Naoki Kimura <i>et al.</i>	
		Filing Date April 20, 2007	Group Art Unit 1643

(37 CFR §1.98(b))

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	5,747,654	05/05/1998	Pastan <i>et al.</i>			
	2	5,892,020	04/06/1999	Mezcs <i>et al.</i>			
	3	2007/0087381	04/19/2007	Kojima			
	4	2008/0107654	05/08/2008	Kikuchi <i>et al.</i>			
	5	2008/0286280	11/20/2008	Kallmeyer <i>et al.</i>			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	6	AU 2002/210917	05/18/2006	Australia			X	
	7	AU 2004/297111	06/23/2005	Australia			X	
	8	EP 1 900 814	03/19/2008	Europe				
	9	JP 10-510842	10/20/1998	Japan			Abstract only	
	10	WO 96/40218	12/19/1996	WIPO				
	11	WO 01/036486	05/25/2001	WIPO				
	12	WO 2008/071394	06/19/2008	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	13	CHOWDHURY <i>et al.</i> , "Engineering scFvs for improved stability," <i>Methods Mol. Biol.</i> , 207:237-54 (2003)
	14	GenBank: U27005.1, <i>Mus musculus</i> , isolate 7183Liv, Vh7183 lg heavy chain variable region gene, Vh region, partial cds, 1 page (April 1996)
	15	GenBank: AY081858.1, <i>Mus musculus</i> , isolate H3-9 anti-GBM immunoglobulin kappa chain variable region mRNA, partial cds, 1 page (March 2004)
	16	JUNG <i>et al.</i> , "The importance of framework residues H6, H7 and H10 in antibody heavy chains: experimental evidence for a new structural subclassification of antibody V(H) domains," <i>J. Mol. Biol.</i> , 309(3):701-16 (2001)
	17	LOFFLER, "A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes," <i>Blood</i> , 95(6):2098-2103 (2000)
	18	FISH & RICHARDSON, Amendment in Reply to Action dated April 23, 2010 in U.S. App. Ser. No. 10/530,696, filed October 22, 2010, 8 pages
	19	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/530,696, mailed January 7, 2011, 9 pages

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0166US1	Application No. 10/582,304
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Naoki Kimura <i>et al.</i>	
		Filing Date April 20, 2007	Group Art Unit 1643

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	20	U.S. EXAMINER PENSEE T. DO, USPTO Final Office Action in U.S. App. Ser. No. 10/582,176, mailed October 29, 2010, 11 pages
	21	FISH & RICHARDSON P.C., Amendment in Reply to Action dated October 29, 2010 in U.S. App. Ser. No. 10/582,176, filed April 28, 2011, 10 pages
	22	FISH & RICHARDSON P.C., Amendment in Reply to Action dated April 16, 2010 in U.S. App. Ser. No. 10/582,413, filed October 15, 2010, 11 pages
	23	U.S. EXAMINER BRADLEY DUFFY, USPTO Final Office Action in U.S. App. Ser. No. 10/582,413, mailed December 23, 2010, 12 pages
	24	FISH & RICHARDSON P.C., Amendment and Response to Restriction Requirement mailed May 3, 2010 in U.S. App. Ser. No. 11/910,117, filed November 2, 2010, 11 pages
	25	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/910,117, mailed January 24, 2011, 10 pages
	26	FISH & RICHARDSON P.C., Response to Restriction Requirement dated March 31, 2010 and Preliminary Amendment in U.S. App. Ser. No. 11/916,981, filed September 29, 2010, 6 pages
	27	U.S. EXAMINER YUNSOO KIM, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/916,981, mailed December 3, 2010, 8 pages
	28	FISH & RICHARDSON P.C., Amendment and Response to Restriction Requirement dated July 1, 2010 in U.S. App. Ser. No. 11/916,979 filed November 30, 2010, 9 pages
	29	U.S. EXAMINER HONG SANG, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/916,979, mailed January 21, 2011, 15 pages
	30	U.S. EXAMINER MEERA NATARAJAN, USPTO Restriction Requirement in U.S. App. Ser. No. 11/916,351, mailed September 3, 2010, 8 pages
	31	FISH & RICHARDSON P.C., Amendment and Response to Restriction Requirement dated September 3, 2010 in U.S. App. Ser. No. 11/916,351, filed December 2, 2010, 9 pages
	32	U.S. EXAMINER ANNE L. HOLLERAN, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/916,351, mailed March 3, 2011, 11 pages
	33	U.S. EXAMINER YAN XIAO, USPTO Restriction Requirement in U.S. App. Ser. No. 12/530,670, mailed March 21, 2011, 7 pages

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	